Key Highlights

  • Tissue Repair (ASX:TRP) closed at $0.11 on 12 November 2026, down 15.39% over the session.
  • Its Appendix 4C for the September 2026 quarter, dated 29 October 2026, reported cash of $4.74 million at quarter end.
  • A US Phase III wound trial has about 112 patients randomised, and a 510(k) submission is targeted for April 2027.

Tissue Repair Limited (ASX:TRP) shares closed at $0.11 on 12 November 2026, down 15.39% over the trading session, while the S&P/ASX 200 closed at 9,146.80, lower by about 6.40 points or roughly 0.07%. Tissue Repair is a medical technology and therapeutics company focused on chronic wound care, with its lead programme TR-987 in a US Phase III trial and a commercial product, TR Pro+, sold in Australia. Its latest update is the Appendix 4C quarterly Cash Flow report, dated 29 October 2026, which covered progress through the September 2026 quarter.

Phase III Trial and Regulatory Timetable

The company said its US Phase III chronic wound trial had approximately 112 patients randomised, with recruitment continuing. It is pursuing a medical device pathway as an alternative route to approval, with a US FDA 510(k) submission targeted for April 2027 and a European CE Mark class II submission expected afterwards. The company also highlighted US reimbursement arrangements introduced in April 2026, which it said could indicate potential reimbursement of about US$1,270 per 10-gram tube in wound clinic settings.

Commercial Launch and Cash Position

TR Pro+ is now in market in Australia in three formats: 10-gram, 30-gram and 200-gram professional back bar. The company resumed direct distribution in the aesthetics channel while keeping its existing medical channel distribution. Cash stood at $4.74 million at quarter end, supplemented by a $1.9 million R&D tax incentive refund received on 1 July 2026. Manufacturing costs were said to be lower after a second-hand centrifuge was procured to accelerate pilot API production.

Sector Context

Tissue Repair operates in the wound care segment, where regulatory pathways, reimbursement rules and commercial distribution all influence how quickly products reach patients. Device pathways can offer a route to market that differs from full drug trials. The S&P/ASX 200 was little changed on the day, so the share price move was specific to Tissue Repair.

Risks and Limitations

The company's cash position of $4.74 million is limited relative to the trial and manufacturing work ahead, and further Capital is likely to be needed. The Phase III trial still needs to complete recruitment and report results, and the proposed device pathway is subject to FDA review. Reimbursement figures are indicative, and actual outcomes will depend on payer decisions.

What to Watch Ahead

Shareholders will be watching the completion of trial recruitment, the preparation of the 510(k) submission targeted for April 2027, and the progress of the manufacturing Supply and GMP agreements. Future quarterly cash flow reports and any capital raising will also be followed.

Final Word

Tissue Repair continues to progress its US trial and device pathway while managing its cash position. The fall in the share price on 12 November took place without a new announcement, and the next Quarterly Report will provide the next update on cash and milestones.